Superior Acute Migraine Treatment Through Transcept & SNBL Deal

277px-Dihydroergotamine.svg

New drug combines combines a muco-adhesive drug carrier of active DHE with a proprietary nasal powder drug delivery device (1)

A new drug that is poised as a rapidly absorbed chemical in the treatment of acute migraines is now on the horizon. The principal or active chemical in the new drug is dihydroergotamine or DHE.

It is anticipated that DHE which for patenting process is known as TO-2070 will provide a novel and potentially improved approach to treatment of acute migraines in patients. TO-2070 is based on a novel nasal powder drug delivery technology. The technology which is developed by Shin Nippon Biomedical Laboratories (SNBL) combines a muco-adhesive drug carrier with a proprietary nasal powder drug delivery device.

Actually DHE is a well-known treatment for treatment of acute migraines and is being used in the US since 1946, however its delivery via the liquid nasal spray route, the subcutaneous route, via intramuscular injections or intravenous shots is hindered by inconvenient administration regimen, slow onset of relief, inconsistent absorption, post-nasal drip and bitter taste. DHE delivery via the pulmonary inhalation method has still not obtained a nod from FDA.

As per the preclinical data this new drug could offer a considerable range of benefits to the migraineur. Such benefits as are not provided by the currently available delivery methods such as injections, pulmonary inhalation etc which prove more inconvenient as well as invasive by nature. (2)

Both Transcept and SNBL have announced that they have entered into an exclusive global licensing agreement. Transcept will pay SNBL an upfront fee, charges through the developmental milestones of the drug as well as following launch and commercialization. This deal will provide Transcept with an advanced nasal powder delivery device and preclinical and clinical services to support the development of TO-2070.

According to Alan Rapoport, M.D., Clinical Professor of Neurology at the David Geffen School of Medicine at UCLA, Los Angeles, CA, and President of the International Headache Society, “DHE has proven to be an excellent treatment for many of the migraine patients who have tried it. This medication can work quickly depending on how it is administered, provides long-lasting relief, has demonstrated a low migraine recurrence rate and can be effectively administered late in the migraine process. Despite these important advantages, the therapeutic impact of DHE has been somewhat limited by challenges associated with the effective delivery of the drug. With this in mind, a novel delivery system that enables the administration of DHE in a convenient way and offers patients rapid and sustained migraine relief, would represent an important advance in the treatment of migraine.” (3)

SOURCES

  1. Image Credits: File:Dihydroergotamine.svg; Wikipedia.com – Wikipmedia Commons; Web September 2013; http://en.wikipedia.org/wiki/File:Dihydroergotamine.svg
  2. Transcept, SNBL Sign Global Licensing Deal For Advanced Acute Migraine Treatment; RTT News; Web September 2013; http://www.rttnews.com/2193740/transcept-snbl-sign-global-licensing-deal-for-advanced-acute-migraine-treatment.aspx?type=bn
  3. Transcept And Shin Nippon Biomedical Laboratories Announce Global Licensing Agreement For Advanced Acute Migraine Treatment; Market Watch – The Wall Street Journal; Web September 2013; http://www.marketwatch.com/story/transcept-and-shin-nippon-biomedical-laboratories-announce-global-licensing-agreement-for-advanced-acute-migraine-treatment-2013-09-25

Copyrights apply on this blog. Please refer copyright permissions.

Advertisements

New Rapid Relief Migraine Drug from MAPP Inc Issued U.S Patent

The US Patent and Trademark Office has issued MAP Pharmaceutical Inc’s new drug under the banner, “Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile.”

Pulmonary Administration DHE from MAPP Issued Patent (1)

The drug’s primary ingredient DHE or Dihydroergotamine is MAPP’s proprietary formulation. The novelty of this new formulation is that it has proved to have rapid efficacy in curbing migraine pain but minimizes the adverse effects that other migraine formulations have.

To be able to achieve quick distribution, metabolization and excretion of the drug, the DHE drug involves pulmonary administration or inhalation of the drug. This is advantageous as the results are almost instantaneous because the drug does not undergo a ‘first-pass effect’ and is absorbed almost entirely into the general blood circulation through the lungs.

The drug has been named LEVADEX® is an orally inhaled investigational drug administered using the Company’s proprietary TEMPO® inhaler for the potential acute treatment of migraine in adults and targets the pharmacokinetic profiles described in this patent. DHE is a drug that is currently available in other dosage forms to treat migraine. (2)

SOURCES:

  1. Image from Ambro; Freedigitalphotos.net; February 2012; http://www.freedigitalphotos.net/images/view_photog.php?photogid=1499
  2. MAP Pharmaceuticals, Inc. (MAPP) Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile; BioSpace; Febraury 2012; http://www.biospace.com/news_story.aspx?StoryID=250731&full=1

Copyrights apply to this blog. Please refer copyright permissions.